Revathi Suppiah1, Laura Wood, Paul Elson, George T Budd. 1. Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R35, Cleveland, Ohio 44195, USA. suppiar@ccf.org
Abstract
BACKGROUND: Based on reports of the efficacy of docetaxel (T) in STS, we undertook a phase I/II trial to determine the response rate (RR), dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of addition of T to doxorubicin (A) and ifosfamide (I) in advanced STS. METHODS: Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial. Dose levels: I-A 40 mg/m(2); I 4.0 gm/m(2); T 40 mg/m(2), II-A 50; I 5.0; T 50, III-A 60; I 6.0; T 60, and IV-A 75; I 7.5; T 75. MTD was defined as the dose producing DLTs in >or=2 of 3-6 patients treated. RESULTS: 21 patients were accrued. Median age: 55 (28-78) years. HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified. MTD was level III (A 60, I 6.0, and T 60). DLT was myelosuppression. All grade 4 toxicities were hematologic. Patients received median 2 cycles (range 2-9). Eight patients (38%) achieved partial response (PR). PR occurred after six cycles in 5 patients. 18 patients died. Median overall survival: 17 months (95% CI, 9.1-33.6 months). CONCLUSIONS: The recommended Phase II dose of this combination is level III: A 60 mg/m(2), I 6.0 g/m(2), T 60 mg/m(2), with mesna and granulocyte-colony stimulating factor. The RR is similar to that of AI in other trials, but the survival is better than anticipated.
BACKGROUND: Based on reports of the efficacy of docetaxel (T) in STS, we undertook a phase I/II trial to determine the response rate (RR), dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of addition of T to doxorubicin (A) and ifosfamide (I) in advanced STS. METHODS:Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial. Dose levels: I-A 40 mg/m(2); I 4.0 gm/m(2); T 40 mg/m(2), II-A 50; I 5.0; T 50, III-A 60; I 6.0; T 60, and IV-A 75; I 7.5; T 75. MTD was defined as the dose producing DLTs in >or=2 of 3-6 patients treated. RESULTS: 21 patients were accrued. Median age: 55 (28-78) years. HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified. MTD was level III (A 60, I 6.0, and T 60). DLT was myelosuppression. All grade 4 toxicities were hematologic. Patients received median 2 cycles (range 2-9). Eight patients (38%) achieved partial response (PR). PR occurred after six cycles in 5 patients. 18 patients died. Median overall survival: 17 months (95% CI, 9.1-33.6 months). CONCLUSIONS: The recommended Phase II dose of this combination is level III: A 60 mg/m(2), I 6.0 g/m(2), T 60 mg/m(2), with mesna and granulocyte-colony stimulating factor. The RR is similar to that of AI in other trials, but the survival is better than anticipated.
Authors: M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: J Verweij; H T Mouridsen; O S Nielssen; P J Woll; R Somers; A T van Oosterom; M Van Glabbeke; T Tursz Journal: Crit Rev Oncol Hematol Date: 1995-10 Impact factor: 6.312
Authors: T Cerny; S Leyvraz; T von Briel; A Küpfer; R Schaad; S F Schmitz; P Honegger; C Sessa; J Brunner; A V Boddy Journal: Ann Oncol Date: 1999-09 Impact factor: 32.976
Authors: K Antman; J Crowley; S P Balcerzak; S E Rivkin; G R Weiss; A Elias; R B Natale; R M Cooper; B Barlogie; D L Trump Journal: J Clin Oncol Date: 1993-07 Impact factor: 44.544
Authors: W J Köstler; T Brodowicz; Y Attems; M Hejna; S Tomek; G Amann; W C Fiebiger; C H Wiltschke; M Krainer; C C Zielinski Journal: Ann Oncol Date: 2001-09 Impact factor: 32.976
Authors: A Le Cesne; E Antoine; M Spielmann; T Le Chevalier; E Brain; C Toussaint; N Janin; L Kayitalire; F Fontaine; J Genin Journal: J Clin Oncol Date: 1995-07 Impact factor: 44.544
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Gerasimos P Vandoros; Theodoros Manolidis; Michalis V Karamouzis; Maria Gkermpesi; Maria Lambropoulou; Athanasios G Papatsoris; Ioannis Zachos; Panagiotis A Konstantinopoulos Journal: Sarcoma Date: 2008-11-18